Beneficial effects of combined ursodeoxycholic acid and angiotensin-II type 1 receptor blocker on hepatic fibrogenesis in a rat model of nonalcoholic steatohepatitis

Journal of Gastroenterology

Volumn 51, Issue 2, 2016, Pages 162-172

  Namisaki, Tadashi ^a   Noguchi, Ryuichi ^a   Moriya, Kei ^a   Kitade, Mitsuteru ^a   Aihara, Yosuke ^a   Douhara, Akitoshi ^a   Nishimura, Norihisa ^a   Takeda, Kosuke ^a   Okura, Yasushi ^a   Kawaratani, Hideto ^a   Takaya, Hiroaki ^a   Seki, Kenichiro ^a   Yoshiji, Hitoshi ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

ARB; Hepatic fibrogenesis; Nonalcoholic steatohepatitis; UDCA

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; CONNECTIVE TISSUE GROWTH FACTOR; FETUIN; GAMMA INTERFERON; INTERLEUKIN 6; LIPOPOLYSACCHARIDE BINDING PROTEIN; PROTEIN ZO1; TOLL LIKE RECEPTOR 4; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; ACTA2 PROTEIN, RAT; ACTIN; AUTACOID; CYTOKINE; ENDOTOXIN; MESSENGER RNA; TLR4 PROTEIN, RAT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTERIAL TRANSLOCATION; CELL ACTIVATION; CONTROLLED STUDY; DIET; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTESTINE MUCOSA PERMEABILITY; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SIGNAL TRANSDUCTION; STELLATE CELL; THERAPY EFFECT; WESTERN BLOTTING; ANIMAL; BIOSYNTHESIS; CELL CULTURE; COMBINATION DRUG THERAPY; COMPLICATION; DRUG EFFECTS; FISCHER 344 RAT; GENETICS; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; PRECLINICAL STUDY; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION;

ACTINS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; CELLS, CULTURED; CYTOKINES; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; ENDOTOXINS; INFLAMMATION MEDIATORS; LIVER CIRRHOSIS; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; RATS, INBRED F344; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; TOLL-LIKE RECEPTOR 4; URSODEOXYCHOLIC ACID;

EID: 84957841204     PISSN: 09441174     EISSN: 14355922     Source Type: Journal    
DOI: 10.1007/s00535-015-1104-x     Document Type: Article

References (36)

1. Lindor KD, Kowdley KV, Heathcote EJ, et al. Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial. Hepatology. 2004;39:770–8.
2. Dufour JF, Oneta CM, Gonvers JJ, et al. Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis. Clin Gastroenterol Hepatol. 2006;4:1537–43.
3. Leuschner UF, Lindenthal B, Herrmann G, et al. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:472–9.
4. Ratziu V, de Ledinghen V, Oberti F, et al. A randomized controlled trial of high-dose ursodeoxycholic acid for nonalcoholic steatohepatitis. J Hepatol. 2011;54:1011–9.
5. Douhara A, Moriya K, Yoshiji H, et al. Reduction of endotoxin attenuates liver fibrosis through suppression of hepatic stellate cell activation and remission of intestinal permeability in a rat non-alcoholic steatohepatitis model. Mol Med Rep. 2015;11:1693–700.
6. Machado MV, Cortez-Pinto H. Gut microbiota and nonalcoholic fatty liver disease. Ann Hepatol. 2012;11:440–9.
7. Bertok L. Effect of bile acids on endotoxin in vitro and in vivo (physico-chemical defense). Bile deficiency and endotoxin translocation. Ann N Y Acad Sci. 1998;851:408–10.
8. Yoshiji H, Yoshii J, Ikenaka Y, et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol. 2002;37:22–30.
9. Yoshiji H, Kuriyama S, Noguchi R, et al. Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets. 2004;4:555–67.
10. Yoshiji H, Kuriyama S, Fukui H. Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol. 2002;23:348–56.
11. Yoshiji H, Kuriyama S, Yoshii J, et al. Angiotensin-II type 1 receptor interaction is a major regulator for liver fibrosis development in rats. Hepatology. 2001;34:745–50.
12. Yoshiji H, Noguchi R, Ikenaka Y, et al. Losartan, an angiotensin-II type 1 receptor blocker, attenuates the liver fibrosis development of non-alcoholic steatohepatitis in the rat. BMC Res Notes. 2009;2:70.
13. Yoshiji H, Noguchi R, Ikenaka Y, et al. Cocktail therapy with a combination of interferon, ribavirin and angiotensin-II type 1 receptor blocker attenuates murine liver fibrosis development. Int J Mol Med. 2011;28:81–8.
14. Shirai Y, Yoshiji H, Noguchi R, et al. Cross talk between Toll-like receptor-4 signaling and angiotensin-II in liver fibrosis development in the rat model of non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2013;28:723–30.
15. Ishizaki K, Iwaki T, Kinoshita S, et al. Ursodeoxycholic acid protects concanavalin A-induced mouse liver injury through inhibition of intrahepatic tumor necrosis factor-alpha and macrophage inflammatory protein-2 production. Eur J Pharmacol. 2008;578:57–64.
16. Setchell KD, Rodrigues CM, Clerici C, et al. Bile acid concentrations in human and rat liver tissue and in hepatocyte nuclei. Gastroenterology. 1997;112:226–35.
17. Michel MC, Foster C, Brunner HR, et al. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev. 2013;65:809–48.
18. Remuzzi A, Perico N, Amuchastegui CS, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol. 1993;4:40–9.
19. Noguchi R, Yoshiji H, Ikenaka Y, et al. Dual blockade of angiotensin-II and aldosterone suppresses the progression of a non-diabetic rat model of steatohepatitis. Hepatol Res. 2013;43:765–74.
20. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–21.
21. Aihara Y, Yoshiji H, Noguchi R, et al. Direct renin inhibitor, aliskiren, attenuates the progression of non-alcoholic steatohepatitis in the rat model. Hepatol Res. 2013;43:1241–50.
22. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med. 2007;13:1324–32.
23. Ulluwishewa D, Anderson RC, McNabb WC, et al. Regulation of tight junction permeability by intestinal bacteria and dietary components. J Nutr. 2011;141:769–76.
24. Trauner M, Graziadei IW. Review article: mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment Pharmacol Ther. 1999;13:979–96.
25. Buko VU, Kuzmitskaya-Nikolaeva IA, Naruta EE, et al. Ursodeoxycholic acid dose-dependently improves liver injury in rats fed a methionine- and choline-deficient diet. Hepatol Res. 2011;41:647–59.
26. Bjornsson E. The clinical aspects of non-alcoholic fatty liver disease. Minerva Gastroenterol Dietol. 2008;54:7–18.
27. Buko VU, Lukivskaya OY, Zavodnik LV, et al. Antioxidative effect of ursodeoxycholic acid in the liver of rats with oxidative stress caused by gamma-irradiation. Ukr Biokhim Zh. 2002;74:88–92.
28. Li X, Wang C, Nie J, et al. Toll-like receptor 4 increases intestinal permeability through up-regulation of membrane PKC activity in alcoholic steatohepatitis. Alcohol. 2013;47:459–65.
29. Guo S, Al-Sadi R, Said HM, et al. Lipopolysaccharide causes an increase in intestinal tight junction permeability in vitro and in vivo by inducing enterocyte membrane expression and localization of TLR-4 and CD14. Am J Pathol. 2013;182:375–87.
30. Bruewer M, Luegering A, Kucharzik T, et al. Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent mechanisms. J Immunol. 2003;171:6164–72.
31. Schwarzenberg SJ, Bundy M. Ursodeoxycholic acid modifies gut-derived endotoxemia in neonatal rats. Pediatr Res. 1994;35:214–7.
32. Sombetzki M, Fuchs CD, Fickert P, et al. 24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. J Hepatol. 2015;62:871–8.
33. Friedman SL. Mechanisms of hepatic fibrogenesis. Gastroenterology. 2008;134:1655–69.
34. Liang TJ, Yuan JH, Tan YR, et al. Effect of ursodeoxycholic acid on TGF beta1/Smad signaling pathway in rat hepatic stellate cells. Chin Med J (Engl). 2009;122:1209–13.
35. Roth S, Michel K, Gressner AM. (Latent) transforming growth factor beta in liver parenchymal cells, its injury-dependent release, and paracrine effects on rat hepatic stellate cells. Hepatology. 1998;27:1003–12.
36. Armendariz-Borunda J, Seyer JM, Kang AH, et al. Regulation of TGF beta gene expression in rat liver intoxicated with carbon tetrachloride. FASEB J. 1990;4:215–21.